Overall, these findings support current medical expert recommendations that metformin should be administered as first-line medical treatment for hyperglycemia during pasireotide therapy, with incretin-based therapies representing an effective option in patients whose hyperglycemia persists [23, 24]. The gene discussed is GCG; the disease is Hyperglycemia.